AI Verdict
LIFX has stronger fundamentals based on our AI analysis.
LIMNW vs LIFX Fundamental Comparison
| Metric | LIMNW | LIFX |
|---|---|---|
| Revenue | N/A | $489.5M |
| Net Income | $-10.2M | $150.8M |
| Net Margin | N/A | 30.8% |
| ROE | N/A | 27.5% |
| ROA | -1,990.4% | 15.7% |
| Current Ratio | 0.05x | 6.26x |
| Debt/Equity | N/A | 0.01x |
| EPS | $-0.43 | $1.77 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LIMNW vs LIFX: Frequently Asked Questions
Is LIMNW or LIFX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LIFX has stronger fundamentals. LIMNW is rated STRONG SELL (95% confidence) while LIFX is rated BUY (72% confidence). This is not investment advice.
How does LIMNW compare to LIFX fundamentally?
Liminatus Pharma, Inc. has ROE of N/A vs Life360, Inc.'s 27.5%. Net margins are N/A vs 30.8% respectively.
Which stock pays higher dividends, LIMNW or LIFX?
LIMNW has a dividend yield of N/A or no dividend while LIFX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LIMNW or LIFX for long term?
For long-term investing, consider that LIMNW has STRONG SELL rating with 95% confidence, while LIFX has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LIMNW vs LIFX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LIMNW vs LIFX, the AI consensus favors LIFX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.